Please amend the application as follows:

**In the claims:**

Please cancel claims 29 and 33-45

1-45. (Cancelled)

Please add new claims 46-56 as follows:

46. (New) A method for inducing or stimulating a T-helper cell response in a human or animal against at least one antigen, while avoiding repeated exposure of vector proteins or vector encoded proteins, the method comprises the steps of:

i. administering a first vaccine composition comprising a first vector encoding said antigen;

ii. administering a second vaccine composition comprising a second vector encoding said antigen and;

iii. administering a third vaccine composition comprising a third vector encoding said antigen;

wherein the first, second and third vectors are not the same;

wherein the first, second and third vaccine compositions are administered sequentially to the animal or human;

wherein at least part of said vectors functions as an adjuvant;. and

wherein the antigen is an antigen of a lentivirus.

47. (New) The method according to claim 46, wherein the lentivirus causes a temporary or long lasting immune impairment.

48. (New) The method according to claim 48, wherein said adjuvant function directs the immune response toward a more T helper 1 type or a more T helper 2 type of response or both.

49. (New) The method according to claim 46, wherein said antigen comprises at least an immunogenic part, derivative and/or analogue of a lentivirus *gag*, *pol*, *rev*, *tat*, *nef*, or *env* protein or a combination thereof.

50. (New) The method according to claim 46, wherein at least one of said vaccine compositions comprises a nucleic acid encoding at least one proteinaceous molecule capable of inducing and/or boosting an immune response against said antigen.

51. (New) The method according to claim 50, wherein said proteinaceous molecule comprises said antigen, or an immunogenic part, derivative or analogue thereof.

52. (New) The method according to claim 50, wherein said nucleic acid comprises a nucleic acid selected from the group consisting of a Semliki Forest Virus, a poxvirus, a herpes virus and an adenovirus, or a combination thereof.

53. (New) The method according to claim 50, wherein said proteinaceous molecule is selected from the group consisting of a co-stimulatory protein, an immune response inhibitory protein, an interleukin, a major histocompatability complex protein and a functional part, derivatives and/or analogues thereof.

54. (New) The method according to claim 46, wherein said vector comprises a nucleic acid which encodes at least one proteinaceous molecule capable of modulating an immune response.

55. (New) The method according to claim 46, wherein said vector is a nucleic acid delivery vehicle comprising said nucleic acid.

56. (New) The method according to claim 55, wherein said nucleic acid delivery vehicle is selected from the group consisting of a Semliki Forest Virus particle, a pox virus particle, a herpes virus particle and an adenovirus particle.